India’s pharmaceutical industry may face export disruptions worth up to Rs 5,000 crore as escalating conflict in West Asia affects shipping routes, raises freight costs, and threatens supply chains for medicines and raw materials.
The FDA has approved Ascendis Pharma’s Yuviwel, a once-weekly treatment for children with achondroplasia. The new therapy offers an alternative to daily injections and showed strong growth results in clinical trials.
The World Health Organization has unveiled critical updates to the influenza vaccine for the 2026-2027 northern hemisphere season, fully refreshing all strains to counter the rapid spread of the new A(H3N2) subclade K variant and...
CDSCO now allows companies to begin lab testing of new drugs immediately after filing applications. The move aims to speed approvals for manufacturing or importing drugs while keeping technical scrutiny for later stages.
Alembic Pharma has received USFDA approval for its generic Lamotrigine Orally Disintegrating Tablets in multiple strengths, boosting its presence in the US generics market and expanding its epilepsy treatment portfolio.
GSK plc will acquire Canada-based 35Pharma for $950 million, adding HS235, a phase I-ready drug candidate for pulmonary hypertension, to strengthen its growing cardiopulmonary pipeline.
Alembic Pharmaceuticals has secured final approval from the FDA for its efinaconazole topical solution, a treatment for toenail fungal infections. This approval strengthens the company’s growing portfolio in the US market.
.jpeg)
Indoco Remedies gets US FDA approval for its generic brivaracetam oral solution, 10 mg/mL, treating partial-onset seizures. Manufactured in Goa, it's a milestone for the company.
Eris Lifesciences has partnered with Natco Pharma to commercialize semaglutide in India, ahead of the patent expiry of the blockbuster diabetes and weight-loss drug ingredient. The launch is expected in March 2026.
Dr. Reddy’s Laboratories Ltd. has secured USFDA review for its proposed interchangeable abatacept biosimilar, DRL_AB, positioning itself as the first to file a BLA in this segment and strengthening its biologics footprint in the US market.
.jpg)
, CDSCO.jpg)
